TIM-3+ endothelial cells modulate T-cell response to lymphoma surrogate antigens by suppressing activation of CD4+ T lymphocytes through the activation of the IL-6-STAT3 pathway, inhibiting Th1 polarization and providing protective immunity [192]. The gene discussed is STAT3; the disease is lymphoma.